Angiotensin in ECMO patients with refractory shock
- PMID: 30382926
- PMCID: PMC6211436
- DOI: 10.1186/s13054-018-2225-4
Angiotensin in ECMO patients with refractory shock
Conflict of interest statement
Ethics approval and consent to participate
The case series includes patients who participated in the ATHOS-3 study or received angiotensin II in the context of a compassionate treatment program. The ATHOS-3 study was fully approved by an independent research ethics committee.
Consent for publication
As part of the ATHOS-3 study, patients gave consent for their data and results to be published in an anonymized format.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Comment in
-
Angiotensin II in ECMO patients: a word of caution.Crit Care. 2019 Apr 26;23(1):144. doi: 10.1186/s13054-019-2337-5. Crit Care. 2019. PMID: 31027494 Free PMC article. No abstract available.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical